Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regadenoson

FDA-approved product (solution, intravenous), marketed as Lexiscan, Regadenoson.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regadenoson
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Myocardial Perfusion Imaging

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other cardiac preparations
FDA pharmacologic class
Adenosine Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli48.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regadenoson in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regadenoson with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

    NCT01618669 · start 2012-06

    Registered record
    Registry ID
    NCT01618669
    Conditions
    Coronary Artery Disease (CAD)
    Interventions
    Regadenoson; Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2014-12
    Enrolment
    1,147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD)
    InterventionRegadenoson; Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
    PhasePhase 3
    Registry statusCompleted

  • Reducing Radioisotope Dose: the Half-Dose CZT Study

    NCT01518777 · start 2012-01

    Registered record
    Registry ID
    NCT01518777
    Conditions
    Coronary Artery Disease
    Interventions
    Half-dose isotope for NuclearStressTest
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01
    Completion
    2016-12-16
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionHalf-dose isotope for NuclearStressTest
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography

    NCT01150578 · start 2011-12

    Registered record
    Registry ID
    NCT01150578
    Conditions
    Myocardial Ischemia
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2011-12
    Completion
    2015-12
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Ischemia
    InterventionNo intervention
    PhaseNot recorded
    Registry statusUnknown

  • Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

    NCT01336140 · start 2011-06

    Registered record
    Registry ID
    NCT01336140
    Conditions
    Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
    Interventions
    Aminophylline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-06
    Completion
    2012-05
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
    InterventionAminophylline; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

    NCT01334918 · start 2011-04-26

    Registered record
    Registry ID
    NCT01334918
    Conditions
    Coronary Artery Disease (CAD)
    Interventions
    regadenoson; technetium Tc99m sestamibi /technetium Tc99m tetrafosmin; Contrast; Single Photon Emission Computed Tomography; Multidetector Computed Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-04-26
    Completion
    2012-07-02
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD)
    Interventionregadenoson; technetium Tc99m sestamibi /technetium Tc99m tetrafosmin; Contrast; Single Photon Emission Computed Tomography +1 more
    PhasePhase 2
    Registry statusCompleted

  • Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

    NCT02092428 · start 2011-04

    Registered record
    Registry ID
    NCT02092428
    Conditions
    Coronary Artery Disease
    Interventions
    Image Quality; Diagnostic Accuracy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2017-03-01
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionImage Quality; Diagnostic Accuracy
    PhasePhase 1
    Registry statusCompleted

  • Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET

    NCT01109992 · start 2011-02

    Registered record
    Registry ID
    NCT01109992
    Conditions
    Coronary Artery Disease
    Interventions
    Exercise plus Regadenoson (Lexercise); Regadenoson (Lexiscan)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-02
    Completion
    2017-06-06
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionExercise plus Regadenoson (Lexercise); Regadenoson (Lexiscan)
    PhasePhase 4
    Registry statusCompleted

  • Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

    NCT01370265 · start 2011-02

    Registered record
    Registry ID
    NCT01370265
    Conditions
    Coronary Artery Disease
    Interventions
    Regadenoson; Adenosine; N-13 ammonia
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-02
    Completion
    2012-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionRegadenoson; Adenosine; N-13 ammonia
    PhaseNot applicable
    Registry statusCompleted

  • Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

    NCT01250496 · start 2010-11

    Registered record
    Registry ID
    NCT01250496
    Conditions
    Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
    Interventions
    Aminophylline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-11
    Completion
    2011-11
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
    InterventionAminophylline; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics

    NCT01719016 · start 2010-08

    Registered record
    Registry ID
    NCT01719016
    Conditions
    Coronary Artery Disease
    Interventions
    Cardiac PET, Coronary catheterization
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2010-08
    Completion
    2027-07-30
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionCardiac PET, Coronary catheterization
    PhaseNot recorded
    Registry statusActive not recruiting

  • Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

    NCT01021865 · start 2010-02

    Registered record
    Registry ID
    NCT01021865
    Conditions
    Coronary Artery Disease; Diabetes Mellitus Type 2
    Interventions
    Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-02
    Completion
    2014-07
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Diabetes Mellitus Type 2
    InterventionGlucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
    PhaseNot recorded
    Registry statusCompleted

  • Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging

    NCT01021618 · start 2010-01

    Registered record
    Registry ID
    NCT01021618
    Conditions
    Coronary Artery Disease; Myocardial Ischemia
    Interventions
    Regadenoson; Symptom-limited exercise
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2012-03
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Myocardial Ischemia
    InterventionRegadenoson; Symptom-limited exercise
    PhaseNot applicable
    Registry statusCompleted

  • Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing

    NCT01026012 · start 2009-12

    Registered record
    Registry ID
    NCT01026012
    Conditions
    Cardiac Function
    Interventions
    regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-12
    Completion
    2010-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Function
    Interventionregadenoson
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

    NCT00894179 · start 2009-10

    Registered record
    Registry ID
    NCT00894179
    Conditions
    Coronary Artery Disease
    Interventions
    regadenoson and atropine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-10
    Completion
    2012-04
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    Interventionregadenoson and atropine
    PhaseNot applicable
    Registry statusTerminated

  • Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

    NCT00881218 · start 2009-06

    Registered record
    Registry ID
    NCT00881218
    Conditions
    Ischemic Heart Disease
    Interventions
    Regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Heart Disease
    InterventionRegadenoson
    PhaseEarly phase 1
    Registry statusCompleted